CellCarta partnered with AI developer Lunit to integrate Lunit’s Scope AI pathology platform into CellCarta’s clinical trial pathology services. The collaboration targets biomarker development, image analysis, and clinical trial testing workflows. CellCarta said the partnership responds to sponsor demand for faster, higher-quality evidence generation, while Lunit emphasized that scalable AI adoption requires interoperability and operational readiness. The firms are assessing pilot opportunities across trial operations and AI image analysis. The deal also positions Lunit’s technology within CellCarta’s global CDx execution footprint, aiming to bridge evidence generation today with potential commercialization workflows as needs evolve.